Targeting Endogenous Inhibitors to Enhance Spinal Axon Regeneration After Injury

靶向内源性抑制剂以增强损伤后脊髓轴突再生

• 批准号: 8018568
• 负责人: RONALD L SCHNAAR
• 金额: $ 35.14万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8018568
• 关键词: Animal Model; Astrocytes; Axon; Behavior; Behavioral; Binding; Biology; Brachial plexus structure; Cardiovascular system; Chondroitin ABC Lyase; Chondroitin Sulfate Proteoglycan; Cicatrix; Contusions; Critiques; Data; Environment; Enzymes; Evaluation; Family; Future; Gangliosides; Health; Human; Implant; In Vitro; Infusion procedures; Injury; Knowledge; Label; Life; Locomotor Recovery; Mediating; Modeling; Molecular; Molecular Target; Molecular Weight; Morbidity - disease rate; Motor Neurons; Myelin; Myelin Associated Glycoprotein; Natural regeneration; Nerve; Neuraminidase; Neuraxis; Neurons; Outcome; Peptides; Phosphatidylinositols; Phospholipase C; Physiological; Polysaccharides; Publishing; Rattus; Reagent; Recovery; Recovery of Function; Reflex action; Research Project Grants; Residual state; Sialoglycoproteins; Side; Signal Transduction; Signaling Molecule; Site; Specificity; Spinal; Spinal Cord; Spinal Cord Contusions; Spinal cord injury; Spinal nerve structure; Study Section; Testing; Therapeutic; Time; Treatment Efficacy; United States National Institutes of Health; autonomic reflex; axon regeneration; base; behavior test; cell type; central nervous system injury; improved; in vivo; inhibitor/antagonist; injured; loss of function; mortality; nerve injury; neurophysiology; neurotrophic factor; novel; oligodendrocyte-myelin glycoprotein; preclinical study; receptor; regenerative; sialoglycolipids; therapeutic development; therapeutic target

DESCRIPTION (provided by applicant): Spinal cord injury typically results in life-long loss of nerve function accompanied by profound morbidity and mortality. The current project will use a well-established animal model for human spinal cord injury - spinal cord contusion in the rat - to investigate novel ways to enhance recovery. Our approach is based on our recent discovery that delivery of the enzyme sialidase to the site of experimental spinal cord injuries results in significant enhancements in spinal axon outgrowth, locomotor recovery, and cardiovascular reflex recovery. We now propose to quantify a battery of behavioral, neurophysiological and neuroanatomical outcomes to explore the potential of sialidase, alone and in combination with other treatments, to enhance recovery after spinal cord injury. Our proposal is based on a wealth of data indicating that central nervous system axons have the capacity to regenerate, but are inhibited from doing so by endogenous axon regeneration inhibitors (ARI's), including myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte-myelin glycoprotein on residual myelin and chondroitin sulfate proteoglycan (CSPG) on the glial scar. Each ARI binds to complementary receptors on axons, halting axon outgrowth. Knowledge of ARI's and ARI receptors provides new opportunities to block ARI actions and enhance recovery. For example, the enzyme sialidase destroys sialoglycans, a class of ARI receptors for MAG, and the enzyme chondroitinase ABC (ChABC) destroys CSPG. Anti-ARI therapies, individually or in combination, may enhance axon regeneration and improve functional recovery after spinal cord injury. We now propose to: (i) Test the hypothesis that sialidase delivery to the site of a spinal cord contusion injury in the rat will enhance axon plasticity and/or regeneration, resulting in significant functional recovery; (ii) Test the hypothesis that combining independent anti-ARI therapies, such as sialidase and ChABC, will result in additive or synergistic enhancements of recovery after spinal cord contusion injury, and (iii) Use our knowledge of sialoglycans and sialidases to identify the molecular target(s) of therapeutic sialidase and discover the best sialidase(s) for preclinical studies. PUBLIC HEALTH RELEVANCE: The mature central nervous system, including the spinal cord, is overwhelmingly inhibitory for axon regeneration, severely limiting recovery after traumatic injury and resulting in life-long loss of function. Remarkably, axons have the ability to regenerate, but are inhibited from doing so by molecules that accumulate at injury sites. Destroying or blocking these molecules may permit axons to regenerate, greatly enhancing functional recovery.

描述（由申请人提供）：脊髓损伤通常导致终身神经功能丧失，并伴有严重的发病率和死亡率。目前的项目将使用一个完善的人类脊髓损伤动物模型——大鼠脊髓挫伤——来研究增强恢复的新方法。我们的方法是基于我们最近的发现，将唾液酸酶输送到实验性脊髓损伤部位，可以显著增强脊髓轴突生长、运动恢复和心血管反射恢复。我们现在建议量化一系列行为，神经生理学和神经解剖学结果，以探索唾液酸酯酶单独或与其他治疗联合使用的潜力，以增强脊髓损伤后的恢复。我们的建议是基于大量数据，表明中枢神经系统轴突具有再生能力，但被内源性轴突再生抑制剂（ARI）所抑制，包括髓鞘相关糖蛋白（MAG）、Nogo和残留髓鞘上的少突胶质细胞-髓鞘糖蛋白和胶质疤痕上的硫酸软骨素蛋白多糖（CSPG）。每个ARI与轴突上的互补受体结合，阻止轴突的生长。了解ARI和ARI受体为阻断ARI作用和促进康复提供了新的机会。例如，唾液酸酶破坏唾液聚糖，一类MAG的ARI受体，而软骨素酶ABC （ChABC）破坏CSPG。抗ari治疗，单独或联合，可以增强轴突再生和改善脊髓损伤后的功能恢复。我们现在建议：(i)验证唾液酸酶递送到大鼠脊髓挫伤部位会增强轴突可塑性和/或再生，从而导致显著的功能恢复的假设；（ii）验证联合使用独立抗ari疗法（如唾液酸酶和ChABC）将导致脊髓挫伤后恢复的附加或协同增强的假设。（iii）利用我们对唾液酸聚糖和唾液酸酶的知识来确定治疗性唾液酸酶的分子靶点，并发现最佳的唾液酸酶用于临床前研究。公共卫生相关性：成熟的中枢神经系统，包括脊髓，对轴突再生具有压倒性的抑制作用，严重限制了创伤性损伤后的恢复并导致终身功能丧失。值得注意的是，轴突具有再生能力，但被损伤部位积聚的分子所抑制。破坏或阻断这些分子可能允许轴突再生，极大地促进功能恢复。